
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Asthma Among Hospitalized Patients with COVID-19 and Related Outcomes
27 Pages Posted: 16 Jul 2020
More...Abstract
Background: Several underlying conditions have been associated with severe SARS-CoV2 illness, but the role of asthma as a comorbidity is not completely understood. Given the high prevalence of asthma in the New York City area, we investigated hospitalized patients with severe COVID-19 disease and the impact of asthma on disease outcomes.
Methods: Electronic heath records were reviewed for 1,298 sequential patients age < 65 years without chronic obstructive pulmonary disease (COPD) who were admitted to our hospital system with a confirmed positive SARS-CoV-2 test.
Results: The overall prevalence of asthma among all hospitalized patients with COVI-19 was 12·6%, yet a higher prevalence (23·6%) was observed in the subset 55 patients <21 years of age. There was no significant difference in hospital length of stay, need for intubation, length of intubation, tracheostomy tube placement, hospital readmission or mortality between asthmatic vs. non-asthmatic patients. Observations between asthmatic and non-asthmatic patients were similar when stratified by obesity, other comorbid conditions (i.e. hypertension, hyperlipidemia, and diabetes), use of controller asthma medication and absolute eosinophil count.
Conclusions: Among hospitalized patients < 65 years with severe COVID-19, asthma diagnosis was not associated with worse outcomes, regardless of age, obesity, or other high-risk comorbidities. Future population based studies are needed to investigate the risk of developing COVID-19 among patients with asthma once universal testing becomes readily available.
Funding Statement: K01 HL140216, Robert Wood Johnson Foundation – Amos Medical Faculty Development Award Program.
Declaration of Interests: The authors have no financial relationships relevant to this article to disclose. Deepti R. Deshpande: Spouse employed by Bristol Myers Squibb.
Ethics Approval Statement: The study was approved by the institutional review board of Columbia University Irving Medical Center under expedited review with a waiver of consent.
Keywords: SARS-CoV2; coronavirus; New York City; respiratory disease
Suggested Citation: Suggested Citation